Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decoy TherapeuticsFRA:FP11 23 3-Year EBITDA Growth Rate is 82.20% as of Jun. 2026, which is 49% above its 10-year median of 55.30. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Decoy Therapeutics ranks better than 96.89% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 82.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 56.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Decoy Therapeutics was 82.20% per year. The lowest was 5.30% per year. And the median was 55.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Decoy Therapeutics 3-Year EBITDA Growth Rate Related Terms
FRA:FP11 vs SLXN, PTIX, SCNI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Decoy Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decoy Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Decoy Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 82.20% mean?
Decoy Therapeutics (FRA:FP11) has a 3-Year EBITDA Growth Rate of 82.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Decoy Therapeutics and its competitors. This is 49% above median its historical median of 55.30. Over the past decade, Decoy Therapeutics' 3-Year EBITDA Growth Rate has ranged from 5.30 to 82.20. According to the industry distribution chart, Decoy Therapeutics ranks #35 out of 1127 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Decoy Therapeutics' 3-Year EBITDA Growth Rate too high?
Decoy Therapeutics' current 3-Year EBITDA Growth Rate of 82.20% is 49% above median its 10-year median of 55.30. Over the past 10 years, this metric has ranged from a low of 5.30 to a high of 82.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Decoy Therapeutics' value of 82.20% is 455.4% above this industry median. Based on the distribution chart, Decoy Therapeutics ranks #35 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' 3-Year EBITDA Growth Rate compare to SLXN and PTIX?
According to the Biotechnology industry distribution chart, Decoy Therapeutics ranks #35 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Decoy Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.80. Decoy Therapeutics' value of 82.20% is 455.4% above this benchmark. Historically, Decoy Therapeutics' own 3-Year EBITDA Growth Rate has ranged from 5.30 to 82.20 over the past decade. While the company's 10-year median is 55.30 vs. the industry median of 14.80, Decoy Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Decoy Therapeutics's current 3-Year EBITDA Growth Rate of 82.20% is 455.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Decoy Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decoy Therapeutics's current 3-Year EBITDA Growth Rate is 82.20%, which is 49% above median its own 10-year median of 55.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current 3-Year EBITDA Growth Rate of 82.20%. The current 3-Year EBITDA Growth Rate is 82.20%, which is 49% above median its 10-year median of 55.30 and 455.4% above the Biotechnology industry median of 14.80. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current 3-Year EBITDA Growth Rate is 82.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score
Get the complete analysis for FRA:FP11
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FP11 has been successfully added to your 
